0YAY.LSE Vitrolife AB
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- 5.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is 0YAY.LSE undervalued?
Graham numberThe Graham number of Vitrolife AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vitrolife AB fundamental analysis
No fundamental analysis for Vitrolife AB yet.
Vitrolife AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vitrolife AB
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorp…
Full company profileVitrolife AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Vitrolife AB annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 856M | 1.05B | 1.15B | 1.48B | 1.25B | 1.68B | 3.23B | 3.51B | 3.61B | 3.44B | 3.23B |
| Gross Profit | 561M | 682M | 761M | 939M | 768M | 1.05B | 1.78B | 1.98B | 2.14B | 1.75B | 1.93B |
| Operating Income | 251M | 343M | 406M | 488M | 367M | 429M | 647M | 738M | 783M | 616M | 596M |
| EBITDA | 292M | 393M | 458M | 560M | 421M | 506M | 991M | 1.11B | 783M | -4.41B | 836M |
| Net Income | 190M | 264M | 310M | 383M | 287M | 341M | 394M | -3.85B | 513M | -5.01B | 404M |
| EPS | 1.75 | 2.43 | 2.85 | 3.53 | 2.64 | 2.97 | 2.91 | -28 | 3.79 | -37 | 2.98 |
| Balance Sheet | |||||||||||
| Total Assets | 1.25B | 1.42B | 1.70B | 2.14B | 2.31B | 19.4B | 20.6B | 16.3B | 17.4B | 11.1B | 11.2B |
| Total Liabilities | 230M | 194M | 201M | 341M | 288M | 4.09B | 3.81B | 3.61B | 3.81B | 3.23B | 3.17B |
| Shareholders' Equity | 1.02B | 1.23B | 1.49B | 1.79B | 2.01B | 15.3B | 16.7B | 12.7B | 13.6B | 7.89B | 8.07B |
| Cash & Short-term Investments | 189M | 396M | 491M | 690M | 974M | 630M | 578M | 861M | 1.14B | 809M | 886M |
| Total Debt | 37.9M | 480K | - | 61.2M | 48.8M | 2.46B | 2.20B | 2.06B | 2.09B | 1.68B | 1.58B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 181M | 312M | 349M | 413M | 356M | 384M | 636M | 757M | 907M | 635M | - |
| Capital Expenditure | 9.97M | 9.50M | 18.4M | 19.1M | 6.77M | 25.0M | 51.0M | 67.0M | 92.0M | 270M | 88.0M |
| Free Cash Flow | 171M | 303M | 331M | 394M | 350M | 359M | 585M | 690M | 907M | 365M | - |
| Ratios | |||||||||||
| ROE | 18.7% | 21.5% | 20.7% | 21.3% | 14.3% | 2.2% | 2.4% | -30.3% | 3.8% | -63.5% | 5.0% |
| ROA | 15.2% | 18.5% | 18.2% | 17.9% | 12.4% | 1.8% | 1.9% | -23.6% | 2.9% | -45.1% | 3.6% |
| Net Profit Margin | 22.2% | 25.2% | 26.9% | 25.9% | 23.0% | 20.3% | 12.2% | -109.7% | 14.2% | -145.7% | 12.5% |
| Debt to Equity | 0.04x | 0.00x | - | 0.03x | 0.02x | 0.16x | 0.13x | 0.16x | 0.15x | 0.21x | 0.20x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Vitrolife AB dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 149M | 1.10 | - |
| 2024 | SEK 135M | 1.00 | 26.3% |
| 2023 | SEK 115M | 0.85 | - |
| 2022 | SEK 109M | 0.81 | 27.7% |
| 2021 | SEK 87.0M | 0.76 | 25.5% |
| 2020 | SEK 88.3M | 0.81 | 30.8% |
| 2019 | SEK 92.3M | 0.85 | 24.1% |
| 2018 | SEK 81.0M | 0.75 | 26.1% |
| 2017 | SEK 56.4M | 0.52 | 21.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on May 17, 2018.
Who owns Vitrolife AB
- Insiders 29.72%
- Institutions 58.15%
- Public & others 12.14%
- Free float 71.0M
Vitrolife AB company profile
- Company name
- Vitrolife AB
- Ticker
- 0YAY.LSE
- ISIN
- SE0011205202
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 1,088
- Fiscal year end
- December
- Address
- Gustaf Werners gata 2, Gothenburg, Sweden, 421 32
- Phone
- 46 31 721 80 00
- Website
- vitrolife.com
About Vitrolife AB
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorporated in 1989 and is based in Gothenburg, Sweden.
Vitrolife AB management
10- Ms. Bronwyn Brophy O´ConnorCEO & President · born 1974
- Mr. Par IhrskogChief Financial Officer · born 1971
- Mr. Olivier DesmaretsChief Operations Officer · born 1979
- Mr. Claus BisgaardSenior Vice President of Technologies · born 1977
- Olivia NatensSenior Vice President of Sales & Marketing · born 1970
- Marcos Jose FernandezVice President Strategy, Sustainability & Corporate Development · born 1968
- Dr. Meishan JinSenior VP & GM of China
- Mr. Rickard EricssonSenior Vice President Innovation · born 1971
- Ricardo CapellaSenior Vice President Genetic Services · born 1968
- Ms. Erin SchardtSenior VP & GM of Americas · born 1978